403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Satellos Bioscience Inc.
(MENAFN- Baystreet) 09:52 AM EST - Satellos Bioscience Inc. : Announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD. Satellos Bioscience Inc.
shares T are trading up $0.02 at $0.67.
shares T are trading up $0.02 at $0.67.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Aixuspeed Reports $500K In Token Commitments Within First 72 Hours Of Pre-Sale
- FBS Analysts Link Fed Signals To A Potential Crypto Comeback
- Young Entrepreneur Rayston Heem Launches Mentorship Program After Early Business Milestone
- ALT5 Sigma Integrates Lightning Network With Voltage To Enable Instant Bitcoin Payments
- Tbtc Launches On Starknet: Expanding Bitcoin's Role In Multi-Chain Defi
- XDC Network's XVC Tech Announces Investment In Laser Digital Carry Fund, Launches Institutional Fund Infrastructure With Libre
More Story
Comments
No comment